Royalty Pharma Income from Continuous Operations 2019-2024 | RPRX
Royalty Pharma income from continuous operations for the twelve months ending June 30, 2024 was $1.030B, a 118.72% increase year-over-year.
- Royalty Pharma annual income from continuous operations for 2023 was $1.7B, a 638.96% increase from 2022.
- Royalty Pharma annual income from continuous operations for 2022 was $0.23B, a 81.46% decline from 2021.
- Royalty Pharma annual income from continuous operations for 2021 was $1.241B, a 27.07% decline from 2020.